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Toward greater efficiency and equity in healthcare resource allocation:
Dr Panos Kanavos to lead consortium in ADVANCE_HTA European
Commission FP7 grant
Healthcare  policymaking  is  increasingly  driven  by  the  need  to  reconcile  mounting  healthcare
system  demands  with  constrained  resources.  This  is  particularly  true  for  medical  technologies
such as pharmaceuticals, medical devices and diagnostics, which comprise a sizeable proportion
of healthcare budgets.  In  the health policy sphere, efforts  to match resources with demands are
often  centred  on  devising  and  implementing  policies  that  deliver  greater  value  for  money.  The
undertaking  of  value  assessments  for  medical  technologies  by  way  of  Health  Technology
Assessment (HTA)  is one such policy  lever  that can be deployed  in achieving this end. Through
the  rigorous  evaluation  of  clinical  and  pharmaco­economic  evidence,  together  with  relevant
stakeholder perspectives, HTA endeavours to inform healthcare resource allocation and decision­
making at the micro­, meso­, and macro­levels of the healthcare system.
In  the  approximately  30  years  of  the  development  of  HTA,  a  substantial  body  of  literature  has
emerged, providing critical evaluation of  the underlying methodologies  that motivate  the practice
and  application  of  HTA.  In  an  attempt  to  investigate  these  areas  in  greater  depth,  Dr.  Panos
Kanavos,  Deputy  Director  of  LSE  Health  and  Programme  Director  of  the  Medical  Technology
Research Group (MTRG), has brought together 13 partners from 9 EU Member States and the US
to  form  a  unique  consortium:  ADVANCE_HTA.  The  project  is  funded  through  the  European
Commission’s  Seventh  Framework  Programme,  and  builds  upon  Dr  Kanavos’  prior  research
contributions  in  areas  such  as  comparative  HTA.  ADVANCE_HTA  is  comprised  of  six,
complementary  streams of  research  that  aim  to advance  the underlying methodologies of HTA,
and to inform the debate by way of:
1. The systematic exploration of different approaches to ensure value for money in resource allocation
decisions;
2. The investigation of alternative frameworks for value assessment and their implementation, including
the consideration and incorporation of relevant and multiple criteria in the decision-making process.
3. The development and validation of a framework for the improved assessment of orphan drugs for rare
diseases.
4. The creation of robust, patient-relevant data by drawing upon and conducting preference elicitation
among the EU-wide patient community, with a view toward informing quality of life measurement
instruments such as the EQ-5D.
5. The identification of strategies for the adaptation and extension of current HTA best practices to
different categories of medical devices.
6. The synthesis of lessons learnt from streams 1-5 in order to propose a set of HTA principles that
encourage capacity building of HTA in emerging jurisdictions.
Given the span of geography  implicated  in ADVANCE_HTA,  the outputs will be broad  in  impact,
while  also  providing  local  relevance.  As  it  relates  to  the  UK  context,  the  three­year  initiative
represents  an  opportune  undertaking  as  the  2009  Pharmaceutical  Price  Regulation  Scheme
(PPRS)  comes  to  a  close  in  December  2013.  Replacing  the  PPRS will  be  a  new  value­based
approach  to  pricing  (VBP)  of  branded  medicines,  as  originally  outlined  in  the  Office  of  Fair
Trading’s  (OFT)  2007  report.  In  their  recent  2010  consultation  document,  the  Department  of
Health highlighted the core elements of this new paradigm. In essence, it is envisaged that pricing
exercises will retain the cost/QALY element, which will be supplemented by a value determination
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